Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2009

01-07-2009 | Original Article

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Authors: Patrick A. Thompson, Gary L. Rosner, Katherine K. Matthay, Theodore B. Moore, Lisa R. Bomgaars, Kenneth J. Ellis, Jamie Renbarger, Stacey L. Berg

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Login to get access

Abstract

Purpose

We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer.

Patients and methods

Children between 1 and 21 years of age, receiving doxorubicin as an infusion of any duration <24 h on either a 1-day or 2-day schedule were eligible if they had no significant abnormality of liver function tests, their dose of doxorubicin was not based on ideal body weight or otherwise “capped,” and they weighed ≥12 kg. Body composition was measured by dual-energy X-ray absorptiometry. Doxorubicin and doxorubicinol concentration in plasma were measured by high pressure liquid chromatography. NONMEM was used to perform pharmacokinetic model fitting and S-PLUS was used to perform a post hoc analysis to examine the effect of body composition on pharmacokinetic parameters.

Results

Twenty-two subjects (16 male; 10 Hispanic, 10 Caucasian, 2 Asian) completed the study. The median age was 15.0 years (range 3.3–21.5), median weight was 51.5 kg (range 12.4–80), median BMI was 19.7 (range 13.2–30.0), and median body fat was 25% (range 15–36). The population mean clearance of doxorubicin was 420 ml/min/m2. Doxorubicinol but not doxorubicin clearance was lower in patients with body fat greater than 30%.

Conclusions

Doxorubicinol clearance is decreased in children with >30% body fat. This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted.
Literature
1.
Asayama K, Ozeki T, Sugihara S, Ito K, Okada T, Tamai H, Takaya R, Hanaki K, Murata M (2003) Criteria for medical intervention in obese children: a new definition of ‘obesity disease’ in Japanese children. Pediatr Int 45:642–646PubMedCrossRef
2.
Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 94:1883–1888PubMed
3.
Berg S, Cowan K, Balis F et al (1994) Pharmacokinetics of Taxol and Doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143–145PubMedCrossRef
4.
Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G (2004) Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 65:259–265PubMedCrossRef
5.
Boucek RJ Jr, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851–15856PubMed
6.
Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L (2003) A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol 51:107–118PubMed
7.
Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21:221–228PubMed
8.
Canal P, Chatelut E, Guichard S (1998) Practical guide for dose individualisation in cancer chemotherapy. Drugs 56:1019–1038PubMedCrossRef
9.
10.
11.
Cindik N, Baskin E, Agras PI, Kinik ST, Turan M, Saatci U (2005) Effect of obesity on inflammatory markers and renal functions. Acta Paediatr 94:1732–1737PubMedCrossRef
12.
Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A (2005) Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108–1110PubMedCrossRef
13.
Crom W, Riley C, Green A et al (1983) Doxorubicin disposition in children and adolescents with cancer. Drug Intell Clin Pharm 17:448
14.
Csernus K, Lanyi E, Erhardt E, Molnar D (2005) Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. Eur J Pediatr 164:44–49PubMedCrossRef
15.
Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53–58PubMedCrossRef
16.
Dobbs N, James C (1987) Estimation of doxorubicin and doxorubicinol by high performance liquid chromatography and advanced automated sample processor. J Chromatogr Biomed Appl 420:184–188CrossRef
17.
Doroshow JH (1996) Anthracyclines and anthracenediones. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy principles and practice. Lippincott-Raven, Philadelphia, pp 409–434
18.
Eksborg S, Palm C, Bjork O (2000) A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs 11:129–136PubMedCrossRef
19.
Fleming R, Eldridge R, Johnson C, Stewart C (1991) Disposition of high-dose methotrexate in an obese cancer patient. Cancer 68:1247–1250PubMedCrossRef
20.
Forrest GL, Gonzalez B, Tseng W, Li X, Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158–5164PubMed
21.
Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Lonnerholm G (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329–337PubMedCrossRef
22.
Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM (2005) Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 46:871–880PubMedCrossRef
23.
Georgiadis MS, Steinberg SM, Hankins LA, Ihde DC, Johnson BE (1995) Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87:361–366PubMedCrossRef
24.
Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436–4440PubMed
25.
Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133PubMedCrossRef
26.
Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267–1273PubMedCrossRef
27.
28.
Hempel G, Flege S, Wurthwein G, Boos J (2002) Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 49:133–141PubMedCrossRef
29.
Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S, Razzouk BI, Ribeiro RC, Rubnitz JE, Hudson MM, Sandlund JT, Pui CH, Relling MV (2006) Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108:3997–4002PubMedCrossRef
30.
Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH (2005) Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 55:488–496PubMedCrossRef
31.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Fety R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46:1051–1068PubMedCrossRef
32.
Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203–211PubMedCrossRef
33.
Lee K, Lee S, Kim SY, Kim SJ, Kim YJ (2007) Percent body fat cutoff values for classifying overweight and obesity recommended by the International Obesity Task Force (IOTF) in Korean children. Asia Pac J Clin Nutr 16:649–655PubMed
34.
Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC (2006) Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg 16:1584–1593PubMedCrossRef
35.
Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25:139–142PubMedCrossRef
36.
Mushlin PS, Cusack BJ, Boucek RJ Jr, Andrejuk T, Li X, Olson RD (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975–982PubMed
37.
38.
Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602–6606PubMed
39.
Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 85:3585–3589PubMedCrossRef
40.
Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, Schmiegelow K, Lonnerholm G (2006) Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385–392PubMedCrossRef
41.
Poikonen P, Blomqvist C, Joensuu H (2001) Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 40:67–71PubMedCrossRef
42.
Ribbing J, Jonsson EN (2004) Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 31:109–134PubMedCrossRef
43.
Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321–1327PubMed
44.
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14:3000–3008PubMed
45.
Santos CA, Boullata JI (2005) An approach to evaluating drug-nutrient interactions. Pharmacotherapy 25:1789–1800PubMedCrossRef
46.
Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945–1952PubMed
47.
Wang GX, Wang YX, Zhou XB, Korth M (2001) Effects of doxorubicinol on excitation–contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423:99–107PubMedCrossRef
Metadata
Title
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Authors
Patrick A. Thompson
Gary L. Rosner
Katherine K. Matthay
Theodore B. Moore
Lisa R. Bomgaars
Kenneth J. Ellis
Jamie Renbarger
Stacey L. Berg
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0854-z

Other articles of this Issue 2/2009

Cancer Chemotherapy and Pharmacology 2/2009 Go to the issue

Original Article

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

Original Article

TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin

Original Article

Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine

Original Article

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

Letter to the Editor

Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view

Original Article

Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits